Lupin launches Clobetasol Propionate Skin cream in US

Clobetasol Propionate cream is "indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

New Delhi: Drug firm Lupin has launched its Clobetasol Propionate cream in the US. The ointment is used for treating inflammation and itching caused by a number of skin conditions.

The company had earlier received approval for the cream in the strength of 0.05 percent from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

The product is a generic version of Fougera Pharmaceuticals Inc's Temovate cream in the same strength, it added.

As per IQVIA MAT June 2018 data, Clobetasol Propionate cream USP 0.05 percent had annual sales of around USD 108.6 million in the US, Lupin said.

Clobetasol Propionate cream is "indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses," it added.

Shares of Lupin today closed at Rs 889.20 per scrip on BSE, up 2.23 percent from the previous close.

Read Also: Lupin launches plaque psoriasis treatment spray in US market